Docetaxel in castration-resistant prostate cancer: A single-centre experience - Abstract

We present a single-institution experience reporting the efficacy and safety of docetaxel, administered as first-line chemotherapy, in castration-resistant prostate cancer (CRPC), focusing on patients and treatment parameters.

From November 2004 to January 2012, 51 patients received chemotherapy with docetaxel. With a mean follow-up time (from the beginning of CHT) of 1.6 years (range 0.1-5.1 years), 35 patients (68.6%) died for prostate cancer and 48 patients (94.1%) showed progression of the disease. Five factors influenced overall survival: nodal status at diagnosis, neoadjuvant hormonal therapy, number of cycles of docetaxel administered, schedule of docetaxel and ECOG performance status before starting chemotherapy.

Written by:
Beatrice D, Davide F, Calogero S, Lucia DB, Mohammed B, Icro M, Vanessa DC, Eleonora MP, Ilaria F, Anna M, Gabriele S, Lorenzo L.   Are you the author?
Department of Radiation-Oncology, University of Florence, Florence, Italy, 1.

Reference: Cancer Invest. 2014 Oct;32(9):445-50.
doi: 10.3109/07357907.2014.958233

 
PubMed Abstract
PMID: 25259606

UroToday.com Prostate Cancer Section

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe